Postmenopausal women with hyperandrogenemia: Three case reports

Table 1 Biochemical parameters determined before and after surgery

Test (units/reference range)	Case 1		Case 2		Case 3
	Before surgery	After surgery	Before surgery	After surgery	Before surgery	After surgery
LH (mUI/mL) (11.3-40.0)	9.91	18.58	16.98	38.61	6.72	ND
FSH (mUI/mL) (9.7-111.0)	22.9	48.7	20.75	107.99	14.88	ND
Total testosterone (ng/dL) (10.83-56.94)	504.5	35.7	258.09	17.5	326.03	21.25
Oestradiol (pg/mL) (< 30)	51	11.8	73.21	10	71.38	ND
Progesterone (ng/mL)	0.49	0.3	0.43	0.1	0.24	ND
Androstenedione (ng/mL) (0.3-3.3)	1.6	ND	2	ND	1.7	ND
DHEA-S (mg/dL)	42.1	ND	50.5	ND	44.3	ND
17 OHP (ng/mL) (0.2–1.7)	1.7	ND	ND	ND	ND	ND
17 OHP (ng/mL) 600 after ACTH stimulation test	0.1	ND	ND	ND	ND	ND

17 OHP: 17 hydroxyprogesterone; ACTH: Adrenocorticotropic hormone; DHEA-S: Dehydroepiandrosterone-sulfate; FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; ND: Not done.

Table 2 Radiological features

	Case 1	Case 2	Case 3
Pelvic ultrasound	Hyperechoic nodule of Ro (12.3 mm)	Hyperechoic mass of Lo (34 mm× 22 mm)	Hyperechoic mass of Lo (45 mm × 20 mm)
Pelvic CT	Nodular slightly dense shadow of Ro with visible enhancement after enhancement	ND	Oval slightly lower density mass of left adnexal area uneven enhancement after enhancement, continuous enhancement in venous phase
Pelvic MRI	Round-shaped abnormal signal range of Ro, T2W1 and DW1 are high signal, higher signal area can be seen in the center	A circular signal shadow of Lo, equal to T1 long and T2 signal, DWI high signal, and obviously enhanced after enhancement	ND

CT: Computed tomography; Lo: Left ovary; MRI: Magnetic resonance imaging; ND: Not done; Ro: Right ovary.